期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 15, 期 12, 页码 1371-1377出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.2015.1110024
关键词
Melanoma; taxanes; albumin-bound paclitaxel; nab-paclitaxel; solvent-free paclitaxel; cremophore-free paclitaxel
类别
Cutaneous melanoma is one of the most aggressive and resistant malignancies in humans. Until recently, progress in the treatment of metastatic melanoma remained dormant for nearly two decades. However, recent advances in immune and targeted therapeutic approaches have led to dramatic and paradigm-shifting advances in the management of metastatic melanoma, that are now leading the way for other malignancies. With the advent of these new therapeutic options, chemotherapy is no longer favored as a first line strategy in metastatic melanoma, but continues to play a role in the salvage treatment of patients that have become refractory to immune-based or targeted therapies. Nab-paclitaxel, a solvent-free alternative to solvent-based paclitaxel, has shown in several trials to be active in metastatic melanoma. Herein, we summarize the role of nab-paclitaxel in the management of patients with advanced melanoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据